FILANA THERAPEUTICS, INC. 8-K

What Happened
On March 12, 2026, Filana Therapeutics, Inc. (NASDAQ: SAVA) filed a Form 8-K under Item 2.02 to furnish a press release reporting its results of operations and financial condition. The press release is attached as Exhibit 99.1 to the 8-K. The company states the information is being furnished (not “filed”) under the Exchange Act and will not be subject to Section 18 liability or incorporated by reference into other filings.

Key Details

• Filing date: March 12, 2026 (Form 8-K).
• Item reported: 2.02 — Results of Operations and Financial Condition.
• Exhibit: 99.1 — Press Release dated March 12, 2026 (furnished with the 8-K).
• Legal note: Information is furnished, not filed, and is not incorporated by reference into other SEC filings.

Why It Matters
This 8-K signals that Filana has provided an update on its recent financial and operating results; investors should read the attached press release for the specific figures (revenue, expenses, net loss/gain, cash position, guidance, if any). The “furnished, not filed” status means the company limited Section 18 liability and the release won’t automatically become part of other registration statements or proxy materials. For trading or portfolio decisions, review the press release and any follow-up SEC filings for the detailed numbers and context.